

Attach to paper 8

Sheet 4 of 2

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

LIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: June 26, 2001

ATTY DOCKET NO.
2001_0206A

SERIAL NO.
09/816,391

APPLICANT
Minoru FUJIMORI

FILING DATE
March 26, 2001

GROUP
1C3S

RECEIVED
JUN 28 2001
TECH CENTER 1600/2

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
AB					

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

BW 1A	AC	K. Low et al., "Lipid A mutant <i>Salmonella</i> with suppressed virulence and TNF α induction retain tumor-targeting <i>in vivo</i> ", Nature Biotechnology, Vol. 17, January 1999, pp. 37-41.
2A	AD	G. Dachs et al., "Targeting gene expression to hypoxic tumor cells", Nature Medicine, Vol. 3, No. 5, May 1997, pp. 515-520.
3A	AE	H. Matsumura et al., "Construction of <i>Escherichia coli</i> - <i>Bifidobacterium longum</i> shuttle vector transforming <i>B. longum</i> 105-A and 108-A", Biosci. Biotech. Biochem., Vol. 61, No. 7, 1997, pp. 1211-1212.
4A	AF	A. Argnani et al., "A convenient and reproducible method to genetically transform bacteria of the genus <i>Bifidobacterium</i> ", Microbiology, Vol. 142, 1996, pp. 109-114.
5A	AG	N. Kimura et al., "Selective localization and growth of <i>Bifidobacterium bifidum</i> in mouse tumors following intravenous administration", Cancer Research, Vol. 40, June 1980, pp. 2061-2068.
BW 6A	AH	M. Fox et al., "Anaerobic bacteria as a delivery system for cancer gene therapy: <i>in vitro</i> activation of 5-fluorocytosine by genetically engineered clostridia", Gene Therapy, Vol. 3, 1996, pp. 173-178.

EXAMINER Brian A. Helling

DATE CONSIDERED 7/25/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PT 19 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: June 26, 2001

ATTY DOCKET NO.
2001_0206A

JUN 26 2001

SERIAL NO.
09/816,391

RECEIVED

APPLICANT
Minoru FUJIMORI et al.

JUN 28 2001

FILING DATE
March 26, 2001

GROUP

1635 TECH CENTER 1600/2

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	BE						
	BF						
	BG						
	BH						
	BI						

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

BW 7/10	BJ	MJ Lemmon et al., "Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment", Gene Therapy, Vol. 4, 1997, pp. 791-796.
8/10	BK	N. Minton et al., "Chemotherapeutic tumour targeting using clostridial spores", FEMS Microbiology Reviews, Vol. 17, 1995, pp. 357-364.
9/10	BL	Proceedings, Fifty-Ninth Annual Meeting of the Japanese Cancer Association, October 4-6, 2000, Yokohama, Vol. 91 Supplement, No. 1880 as well as its English translation and Verification of translation.
DW 10/10	BM	Yazawa et al., Cancer Gene Therapy, Vol. 7, pp. 269-274 published on March 27, 2000 as well as a copy of the certificate.

EXAMINER

Boris A. Hines

DATE CONSIDERED

3/2/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Attach to paper no. 11

RECEIVED

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: September 25, 2001

ATTY DOCKET NO.

01829/010515A 2001_0206A

SERIAL NO.

09/816,391

SEP 26 2001

APPLICANT

Minoru FUJIMORI et al.

TECH CENTER 1600/2900

FILING DATE

March 26, 2001

GROUP

T642 1635

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AF						
	AG						

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

BW 1	AH	C. Tacket et al., "Comparison of the Safety and Immunogenicity of ΔaroC ΔaroD and Δcya Δcrp <i>Salmonella typhi</i> Strains in Adult Volunteers", <i>Infection and Immunity</i> , Vol. 60, No. 2, pp. 536-541, February 1992.
2	AI	H. Yasui et al., "Enhancement of Immune Response in Peyer's Patch Cells Cultured with <i>Bifidobacterium breve</i> ", <i>Journal of Dairy Science</i> , Vol. 74, pp. 1187-1195, 1991.
3	AJ	D. Saltzman et al., "Attenuated <i>Salmonella typhimurium</i> Containing Interleukin-2 Decreases MC-38 Hepatic Metastases: A Novel Anti-tumor Agent", <i>Cancer Biotherapy and Radiopharmaceuticals</i> , Vol. 11, No. 2, pp. 145-153, 1996.
4	AK	J. Saavedra et al., "Feeding of <i>Bifidobacterium bifidum</i> and <i>Streptococcus thermophilus</i> to Infants in Hospital for Prevention of Diarrhoea and Shedding of Rotavirus", <i>The Lancet</i> , Vol. 344, pp. 1046-1049, October 15, 1994.
5	AL	B. Reddy et al., "Inhibitory Effect of <i>Bifidobacterium longum</i> on Colon, Mannary, and Liver Carcinogenesis Induced by 2-Amino-3-methylimidazo[4,5-f]quinoline, a Food Mutagen", <i>Cancer Research</i> , Vol. 53, pp. 3914-3918, September 1, 1993.
BW 6	AM	D. Hone et al., "Evaluation in Volunteers of a Candidate Live Oral Attenuated <i>Salmonella typhi</i> Vector Vaccine", <i>Journal of Clinical Investigation</i> , Vol. 90, pp. 412-420, 1992.

EXAMINER

B Min & Hux

DATE CONSIDERED

3/25/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.